Detailed throughout this report are existing commitments, such as CSL’s emissions reduction targets, and new initial commitments in support of performance across the focus areas detailed above. This includes a new initial commitment for Biodiversity and the expansion of the Company’s Access and affordability commitment. Find out more in the Healthier World section, from page 26. * Limited assurance in FY2024 by Deloitte. MATERIAL TOPICS* FOCUS AREAS + READ MORE ON PAGES 35–39 Donor experience – create best-in‑class donor experience in partnership with donors and communities Patient experience – elevate patient experience in drug development by embedding patient insights and lived experience Access and affordability – advance equitable access to medicines and vaccines Talent and culture – attract, develop, engage and retain top talent with diverse identities, cultures, backgrounds, skills and lived experiences Supplier – partner with suppliers/third parties who share CSL’s commitment to social and environmental responsibility Energy – undertake initiatives that reduce emissions internally and across its supply chain Waste – divert waste from landfill through reducing, reusing, recycling and composting Water – identify, prioritise and implement water reduction initiatives Biodiversity – mitigate the impact of business activities on nature through its direct operations and increase the resiliency of its supply chain via sustainable sourcing • Product innovation and research • Employee development and retention • Affordability and access to health • Product quality and safety • Clinical trial practices • Plasma donations • Employee health, safety and wellbeing • Environmental management • Climate and carbon, and energy efficiency • Ecosystems and biodiversity • Circularity, waste and resource management + READ MORE ON PAGES 20–24 + READ MORE ON PAGES 8 AND 25 + READ MORE ON PAGES 27–34 HEALTHIER COMMUNITIES HEALTHIER ENVIRONMENT Sustainability governance • Business ethics, integrity and compliance • Data protection and cybersecurity + READ MORE ON PAGES 49–51 13 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3